PHAR300 Pharmacotherapy I Exam Prep – Real Practice Questions, Answers &
Detailed Rationales (Updated 2026) | Pharmacokinetics &
Pharmacodynamics, Drug Therapy Management, Cardiovascular & Respiratory
Medications, Antibiotics & Antimicrobial Therapy, Endocrine & GI
Pharmacotherapy, Adverse Drug Reactions, Clinical Case Studies, Medication
Safety & Patient Care Planning
Question 1: A 68-year-old male with hypertension, type 2 diabetes, and chronic
kidney disease (eGFR 45 mL/min/1.73m²) presents for medication management.
Which antihypertensive agent is MOST appropriate as initial therapy to provide
both blood pressure control and renal protection?
A. Hydrochlorothiazide
B. Amlodipine
C. Lisinopril
D. Metoprolol succinate
CORRECT ANSWER: C. Lisinopril
Rationale: ACE inhibitors like lisinopril are first-line for hypertensive patients with
diabetes and CKD because they reduce intraglomerular pressure, decrease proteinuria,
and slow progression of renal disease. They provide cardiovascular and renal protective
benefits beyond blood pressure lowering, making them preferred in this patient
population per KDIGO and ACC/AHA guidelines.
Question 2: Which of the following best describes the mechanism by which
sacubitril/valsartan improves outcomes in heart failure with reduced ejection
fraction (HFrEF)?
A. Selective beta-1 receptor blockade reducing myocardial oxygen demand
B. Dual inhibition of neprilysin and angiotensin II receptor type 1
C. Aldosterone receptor antagonism preventing sodium retention
D. Direct vasodilation via nitric oxide pathway activation
CORRECT ANSWER: B. Dual inhibition of neprilysin and angiotensin II receptor type
1
Rationale: Sacubitril/valsartan is an angiotensin receptor-neprilysin inhibitor (ARNI).
Sacubitril inhibits neprilysin, increasing natriuretic peptides that promote vasodilation
and natriuresis, while valsartan blocks angiotensin II type 1 receptors, reducing
vasoconstriction and aldosterone release. This dual mechanism provides superior
outcomes compared to ACE inhibitors alone in HFrEF.
Question 3: A patient with atrial fibrillation and a CHA₂DS₂-VASc score of 4 requires
anticoagulation. Which factor would MOST strongly favor choosing apixaban over
warfarin?
A. Patient preference for once-daily dosing
B. History of mechanical mitral valve replacement
,C. Severe hepatic impairment (Child-Pugh C)
D. Need for frequent INR monitoring avoidance
CORRECT ANSWER: D. Need for frequent INR monitoring avoidance
Rationale: Apixaban, a direct oral anticoagulant (DOAC), does not require routine INR
monitoring, unlike warfarin. This improves convenience and adherence. However,
apixaban is contraindicated in mechanical heart valves (option B) and severe hepatic
impairment (option C). While apixaban is twice daily (not once daily), the avoidance of
monitoring is a key advantage.
Question 4: In the management of acute decompensated heart failure with
pulmonary edema, which intervention provides the MOST rapid reduction in
preload?
A. Intravenous furosemide
B. Sublingual nitroglycerin
C. Oral spironolactone
D. Intravenous milrinone
CORRECT ANSWER: B. Sublingual nitroglycerin
Rationale: Nitroglycerin acts within minutes to cause venodilation, rapidly reducing
preload and pulmonary congestion. IV furosemide has a slower onset (30 minutes) and
primarily works through diuresis. Spironolactone is not used acutely. Milrinone is an
inodilator used in cardiogenic shock but does not reduce preload as rapidly as
nitroglycerin.
Question 5: Which statement regarding statin therapy in primary prevention of
cardiovascular disease is MOST accurate?
A. Statins should be initiated in all adults over age 50 regardless of risk factors
B. The decision to start statins should be based on calculated 10-year ASCVD risk
≥7.5%
C. High-intensity statins are preferred for all patients with diabetes
D. Statins are contraindicated in patients with baseline LDL <100 mg/dL
CORRECT ANSWER: B. The decision to start statins should be based on calculated
10-year ASCVD risk ≥7.5%
Rationale: ACC/AHA guidelines recommend using the Pooled Cohort Equations to
estimate 10-year ASCVD risk. Statin therapy is indicated for primary prevention when
risk is ≥7.5% after clinician-patient risk discussion. Not all adults >50 need statins (A),
high-intensity statins are not universally required in diabetes (C), and statins may still
benefit patients with LDL <100 mg/dL if overall risk is high (D).
Question 6: A patient with stable angina is prescribed sublingual nitroglycerin for
acute symptom relief. Which instruction is MOST critical for proper use?
,A. Take with a full glass of water to enhance absorption
B. Store tablets in the original amber glass bottle away from light
C. Swallow tablets whole for sustained effect
D. Take prophylactically every 4 hours regardless of symptoms
CORRECT ANSWER: B. Store tablets in the original amber glass bottle away from
light
Rationale: Nitroglycerin tablets are highly sensitive to light, moisture, and air, which
degrade potency. They must be stored in the original tightly closed amber glass
container. Tablets should be placed under the tongue and allowed to dissolve (not
swallowed), and used only as needed for acute angina or prophylactically before
exertion, not on a fixed schedule.
Question 7: Which antiarrhythmic medication is classified as Vaughan Williams
Class III and primarily prolongs the action potential duration by blocking potassium
channels?
A. Lidocaine
B. Flecainide
C. Amiodarone
D. Verapamil
CORRECT ANSWER: C. Amiodarone
Rationale: Amiodarone is a Class III antiarrhythmic that predominantly blocks
potassium channels, prolonging repolarization and the QT interval. Lidocaine is Class IB
(sodium channel blocker), flecainide is Class IC (potent sodium channel blocker), and
verapamil is Class IV (calcium channel blocker).
Question 8: In a patient with heart failure with preserved ejection fraction (HFpEF),
which medication has demonstrated the MOST consistent mortality benefit in
clinical trials?
A. Lisinopril
B. Metoprolol
C. Spironolactone
D. None of the above have shown definitive mortality benefit
CORRECT ANSWER: D. None of the above have shown definitive mortality benefit
Rationale: Unlike HFrEF, no pharmacologic therapy has consistently demonstrated
mortality reduction in HFpEF across large randomized trials. While some agents like
spironolactone (TOPCAT trial) showed modest benefits in subgroups, overall mortality
benefit remains unproven. Management focuses on symptom control and comorbidity
management.
Question 9: Which of the following is a contraindication to initiating an angiotensin-
converting enzyme (ACE) inhibitor?
, A. History of dry cough
B. Bilateral renal artery stenosis
C. Mild hyperkalemia (K⁺ 5.2 mEq/L)
D. Age >75 years
CORRECT ANSWER: B. Bilateral renal artery stenosis
Rationale: ACE inhibitors are contraindicated in bilateral renal artery stenosis (or
stenosis in a solitary kidney) because they can cause acute renal failure by reducing
glomerular filtration pressure. Dry cough is a common side effect but not a
contraindication. Mild hyperkalemia requires monitoring but is not an absolute
contraindication. Age alone is not a contraindication.
Question 10: A patient with hypertension is started on chlorthalidone. Which
electrolyte abnormality is MOST likely to develop with chronic therapy?
A. Hyperkalemia
B. Hypocalcemia
C. Hypokalemia
D. Hypermagnesemia
CORRECT ANSWER: C. Hypokalemia
Rationale: Thiazide diuretics like chlorthalidone increase distal tubular sodium delivery,
enhancing potassium excretion via the Na⁺/K⁺ exchange mechanism, leading to
hypokalemia. They may cause mild hypercalcemia (not hypocalcemia) and
hypomagnesemia. Hyperkalemia is associated with potassium-sparing diuretics or
RAAS inhibitors.
Question 11: Which beta-blocker is MOST appropriate for a patient with heart
failure with reduced ejection fraction (HFrEF) and concurrent asthma?
A. Propranolol
B. Carvedilol
C. Metoprolol tartrate
D. Atenolol
CORRECT ANSWER: B. Carvedilol
Rationale: While all beta-blockers carry some risk in asthma, carvedilol and metoprolol
succinate (not tartrate) are the only beta-blockers with proven mortality benefit in
HFrEF. Carvedilol has non-selective beta and alpha-1 blocking activity but is still
preferred over non-cardioselective agents like propranolol. However, caution is
required; if asthma is severe, alternatives may be considered. Among guideline-directed
options, carvedilol is acceptable with monitoring.
Question 12: In the treatment of hypertensive emergency with acute pulmonary
edema, which intravenous agent is preferred for rapid, titratable blood pressure
control?
Detailed Rationales (Updated 2026) | Pharmacokinetics &
Pharmacodynamics, Drug Therapy Management, Cardiovascular & Respiratory
Medications, Antibiotics & Antimicrobial Therapy, Endocrine & GI
Pharmacotherapy, Adverse Drug Reactions, Clinical Case Studies, Medication
Safety & Patient Care Planning
Question 1: A 68-year-old male with hypertension, type 2 diabetes, and chronic
kidney disease (eGFR 45 mL/min/1.73m²) presents for medication management.
Which antihypertensive agent is MOST appropriate as initial therapy to provide
both blood pressure control and renal protection?
A. Hydrochlorothiazide
B. Amlodipine
C. Lisinopril
D. Metoprolol succinate
CORRECT ANSWER: C. Lisinopril
Rationale: ACE inhibitors like lisinopril are first-line for hypertensive patients with
diabetes and CKD because they reduce intraglomerular pressure, decrease proteinuria,
and slow progression of renal disease. They provide cardiovascular and renal protective
benefits beyond blood pressure lowering, making them preferred in this patient
population per KDIGO and ACC/AHA guidelines.
Question 2: Which of the following best describes the mechanism by which
sacubitril/valsartan improves outcomes in heart failure with reduced ejection
fraction (HFrEF)?
A. Selective beta-1 receptor blockade reducing myocardial oxygen demand
B. Dual inhibition of neprilysin and angiotensin II receptor type 1
C. Aldosterone receptor antagonism preventing sodium retention
D. Direct vasodilation via nitric oxide pathway activation
CORRECT ANSWER: B. Dual inhibition of neprilysin and angiotensin II receptor type
1
Rationale: Sacubitril/valsartan is an angiotensin receptor-neprilysin inhibitor (ARNI).
Sacubitril inhibits neprilysin, increasing natriuretic peptides that promote vasodilation
and natriuresis, while valsartan blocks angiotensin II type 1 receptors, reducing
vasoconstriction and aldosterone release. This dual mechanism provides superior
outcomes compared to ACE inhibitors alone in HFrEF.
Question 3: A patient with atrial fibrillation and a CHA₂DS₂-VASc score of 4 requires
anticoagulation. Which factor would MOST strongly favor choosing apixaban over
warfarin?
A. Patient preference for once-daily dosing
B. History of mechanical mitral valve replacement
,C. Severe hepatic impairment (Child-Pugh C)
D. Need for frequent INR monitoring avoidance
CORRECT ANSWER: D. Need for frequent INR monitoring avoidance
Rationale: Apixaban, a direct oral anticoagulant (DOAC), does not require routine INR
monitoring, unlike warfarin. This improves convenience and adherence. However,
apixaban is contraindicated in mechanical heart valves (option B) and severe hepatic
impairment (option C). While apixaban is twice daily (not once daily), the avoidance of
monitoring is a key advantage.
Question 4: In the management of acute decompensated heart failure with
pulmonary edema, which intervention provides the MOST rapid reduction in
preload?
A. Intravenous furosemide
B. Sublingual nitroglycerin
C. Oral spironolactone
D. Intravenous milrinone
CORRECT ANSWER: B. Sublingual nitroglycerin
Rationale: Nitroglycerin acts within minutes to cause venodilation, rapidly reducing
preload and pulmonary congestion. IV furosemide has a slower onset (30 minutes) and
primarily works through diuresis. Spironolactone is not used acutely. Milrinone is an
inodilator used in cardiogenic shock but does not reduce preload as rapidly as
nitroglycerin.
Question 5: Which statement regarding statin therapy in primary prevention of
cardiovascular disease is MOST accurate?
A. Statins should be initiated in all adults over age 50 regardless of risk factors
B. The decision to start statins should be based on calculated 10-year ASCVD risk
≥7.5%
C. High-intensity statins are preferred for all patients with diabetes
D. Statins are contraindicated in patients with baseline LDL <100 mg/dL
CORRECT ANSWER: B. The decision to start statins should be based on calculated
10-year ASCVD risk ≥7.5%
Rationale: ACC/AHA guidelines recommend using the Pooled Cohort Equations to
estimate 10-year ASCVD risk. Statin therapy is indicated for primary prevention when
risk is ≥7.5% after clinician-patient risk discussion. Not all adults >50 need statins (A),
high-intensity statins are not universally required in diabetes (C), and statins may still
benefit patients with LDL <100 mg/dL if overall risk is high (D).
Question 6: A patient with stable angina is prescribed sublingual nitroglycerin for
acute symptom relief. Which instruction is MOST critical for proper use?
,A. Take with a full glass of water to enhance absorption
B. Store tablets in the original amber glass bottle away from light
C. Swallow tablets whole for sustained effect
D. Take prophylactically every 4 hours regardless of symptoms
CORRECT ANSWER: B. Store tablets in the original amber glass bottle away from
light
Rationale: Nitroglycerin tablets are highly sensitive to light, moisture, and air, which
degrade potency. They must be stored in the original tightly closed amber glass
container. Tablets should be placed under the tongue and allowed to dissolve (not
swallowed), and used only as needed for acute angina or prophylactically before
exertion, not on a fixed schedule.
Question 7: Which antiarrhythmic medication is classified as Vaughan Williams
Class III and primarily prolongs the action potential duration by blocking potassium
channels?
A. Lidocaine
B. Flecainide
C. Amiodarone
D. Verapamil
CORRECT ANSWER: C. Amiodarone
Rationale: Amiodarone is a Class III antiarrhythmic that predominantly blocks
potassium channels, prolonging repolarization and the QT interval. Lidocaine is Class IB
(sodium channel blocker), flecainide is Class IC (potent sodium channel blocker), and
verapamil is Class IV (calcium channel blocker).
Question 8: In a patient with heart failure with preserved ejection fraction (HFpEF),
which medication has demonstrated the MOST consistent mortality benefit in
clinical trials?
A. Lisinopril
B. Metoprolol
C. Spironolactone
D. None of the above have shown definitive mortality benefit
CORRECT ANSWER: D. None of the above have shown definitive mortality benefit
Rationale: Unlike HFrEF, no pharmacologic therapy has consistently demonstrated
mortality reduction in HFpEF across large randomized trials. While some agents like
spironolactone (TOPCAT trial) showed modest benefits in subgroups, overall mortality
benefit remains unproven. Management focuses on symptom control and comorbidity
management.
Question 9: Which of the following is a contraindication to initiating an angiotensin-
converting enzyme (ACE) inhibitor?
, A. History of dry cough
B. Bilateral renal artery stenosis
C. Mild hyperkalemia (K⁺ 5.2 mEq/L)
D. Age >75 years
CORRECT ANSWER: B. Bilateral renal artery stenosis
Rationale: ACE inhibitors are contraindicated in bilateral renal artery stenosis (or
stenosis in a solitary kidney) because they can cause acute renal failure by reducing
glomerular filtration pressure. Dry cough is a common side effect but not a
contraindication. Mild hyperkalemia requires monitoring but is not an absolute
contraindication. Age alone is not a contraindication.
Question 10: A patient with hypertension is started on chlorthalidone. Which
electrolyte abnormality is MOST likely to develop with chronic therapy?
A. Hyperkalemia
B. Hypocalcemia
C. Hypokalemia
D. Hypermagnesemia
CORRECT ANSWER: C. Hypokalemia
Rationale: Thiazide diuretics like chlorthalidone increase distal tubular sodium delivery,
enhancing potassium excretion via the Na⁺/K⁺ exchange mechanism, leading to
hypokalemia. They may cause mild hypercalcemia (not hypocalcemia) and
hypomagnesemia. Hyperkalemia is associated with potassium-sparing diuretics or
RAAS inhibitors.
Question 11: Which beta-blocker is MOST appropriate for a patient with heart
failure with reduced ejection fraction (HFrEF) and concurrent asthma?
A. Propranolol
B. Carvedilol
C. Metoprolol tartrate
D. Atenolol
CORRECT ANSWER: B. Carvedilol
Rationale: While all beta-blockers carry some risk in asthma, carvedilol and metoprolol
succinate (not tartrate) are the only beta-blockers with proven mortality benefit in
HFrEF. Carvedilol has non-selective beta and alpha-1 blocking activity but is still
preferred over non-cardioselective agents like propranolol. However, caution is
required; if asthma is severe, alternatives may be considered. Among guideline-directed
options, carvedilol is acceptable with monitoring.
Question 12: In the treatment of hypertensive emergency with acute pulmonary
edema, which intravenous agent is preferred for rapid, titratable blood pressure
control?
